{"disease":{"id":"moderate-hemophilia","name":"moderate hemophilia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05181618","title":"A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":136,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04158648","title":"A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04024176","title":"Gait Analysis in Moderate Hemophiliac Patients (AQM-Hemophile)","phase":"NA","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Nantes University Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}